Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.80 +3.8%	$6.55	$4.34 ▼ $12.38	$341.83M	0.46	166,105 shs	148,610 shs
HUMA Humacyte	$2.48 +0.4%	$2.40	$1.15 ▼ $8.24	$384.70M	1.9	3.97 million shs	10.02 million shs
KOD Kodiak Sciences	$7.90 -3.7%	$5.05	$1.92 ▼ $11.60	$416.84M	2.41	651,270 shs	416,645 shs
QNCX Quince Therapeutics	$1.65 -1.2%	$1.55	$0.51 ▼ $2.45	$88.48M	1.02	207,301 shs	188,608 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	+3.82%	+0.89%	+3.19%	+30.02%	-16.97%
HUMA Humacyte	+0.40%	+8.77%	-2.36%	+108.40%	-68.33%
KOD Kodiak Sciences	-3.66%	+18.80%	+77.93%	+109.55%	+239.06%
QNCX Quince Therapeutics	-1.20%	-1.79%	-3.51%	+61.76%	+139.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	1.95 of 5 stars	3.6	0.0	0.0	2.1	3.3	0.0
HUMA Humacyte	1.701 of 5 stars	3.5	1.0	0.0	1.9	0.8	0.6
KOD Kodiak Sciences	3.1679 of 5 stars	2.0	1.0	4.6	2.7	3.3	0.0
QNCX Quince Therapeutics	3.0248 of 5 stars	3.7	3.0	0.0	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.25	Buy	$22.00	223.53% Upside
HUMA Humacyte	3.00	Buy	$11.71	372.35% Upside
KOD Kodiak Sciences	2.00	Hold	$9.00	13.92% Upside
QNCX Quince Therapeutics	3.30	Buy	$8.29	402.16% Upside

Current Analyst Ratings Breakdown

Latest QNCX, HUMA, KOD, and AURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2025	QNCX Quince Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
8/5/2025	QNCX Quince Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$9.00
8/5/2025	QNCX Quince Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$9.00
7/23/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/17/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
7/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/13/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/4/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
HUMA Humacyte	$1.57M	245.03	N/A	N/A	($0.41) per share	-6.05
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.86 per share	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	$0.69 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/14/2025 (Estimated)
HUMA Humacyte	-$148.70M	-$0.69	N/A	N/A	N/A	N/A	N/A	-73.59%	8/11/2025 (Estimated)
KOD Kodiak Sciences	-$176.21M	-$3.63	N/A	N/A	N/A	N/A	-115.71%	-54.17%	8/13/2025 (Estimated)
QNCX Quince Therapeutics	-$56.83M	-$1.39	N/A	N/A	N/A	N/A	-117.52%	-34.22%	8/12/2025 (Estimated)

Latest QNCX, HUMA, KOD, and AURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AURA Aura Biosciences	-$0.47	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	KOD Kodiak Sciences	-$1.01	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	QNCX Quince Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	HUMA Humacyte	-$0.15	N/A	N/A	N/A	$0.94 million	N/A
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/13/2025	Q1 2025	HUMA Humacyte	-$0.19	-$0.10	+$0.09	$0.28	$0.46 million	$0.52 million
5/13/2025	Q1 2025	QNCX Quince Therapeutics	-$0.24	-$0.34	-$0.10	-$0.34	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	11.06	11.06
HUMA Humacyte	0.36	3.68	3.28
KOD Kodiak Sciences	N/A	4.62	4.62
QNCX Quince Therapeutics	0.82	4.05	4.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
HUMA Humacyte	44.71%
KOD Kodiak Sciences	89.06%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	5.40%
HUMA Humacyte	5.10%
KOD Kodiak Sciences	45.90%
QNCX Quince Therapeutics	20.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	50.27 million	47.55 million	Not Optionable
HUMA Humacyte	150	155.12 million	147.21 million	Optionable
KOD Kodiak Sciences	90	52.76 million	28.55 million	Optionable
QNCX Quince Therapeutics	60	53.62 million	42.74 million	Optionable

QNCX, HUMA, KOD, and AURA Headlines

Recent News About These Companies

Quince Therapeutics (QNCX) Projected to Post Earnings on Tuesday

August 6 at 10:28 AM | marketbeat.com

JMP Securities Begins Coverage on Quince Therapeutics (NASDAQ:QNCX)

August 6 at 9:20 AM | marketbeat.com

Quince Therapeutics (NASDAQ:QNCX) Now Covered by Analysts at Citizens Jmp

August 6 at 7:31 AM | marketbeat.com

Quince Therapeutics (NASDAQ:QNCX) Coverage Initiated at Citizens Jmp

August 6 at 4:49 AM | americanbankingnews.com

Quince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Up 64.5% in July

August 6 at 4:05 AM | marketbeat.com

JMP Securities Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX)

August 6 at 3:33 AM | americanbankingnews.com

JMP Securities Initiates Coverage of Quince Therapeutics (QNCX) with Market Outperform Recommendation

August 5, 2025 | msn.com

Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of "Buy" by Analysts

July 21, 2025 | marketbeat.com

Brookline Capital Management Comments on QNCX Q3 Earnings

July 21, 2025 | marketbeat.com

Quince Therapeutics, Inc. (QNCX) - Yahoo Finance

July 17, 2025 | finance.yahoo.com

Quince Therapeutics' (QNCX) "Buy" Rating Reaffirmed at D. Boral Capital

July 17, 2025 | marketbeat.com

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

July 16, 2025 | businesswire.com

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan ...

July 12, 2025 | finance.yahoo.com

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

July 10, 2025 | businesswire.com

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

June 25, 2025 | businesswire.com

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

June 18, 2025 | businesswire.com

Quince Therapeutics raises $11.5 million in private placement

June 14, 2025 | investing.com

Quince Therapeutics Raises $11.5M in Private Placement

June 13, 2025 | tipranks.com

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

June 12, 2025 | businesswire.com

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

June 3, 2025 | businesswire.com

Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026

May 15, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, HUMA, KOD, and AURA Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.80 +0.25 (+3.82%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$6.81 +0.01 (+0.15%)

As of 08/8/2025 05:46 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Humacyte NASDAQ:HUMA

$2.48 +0.01 (+0.40%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.54 +0.06 (+2.22%)

As of 08/8/2025 07:59 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Kodiak Sciences NASDAQ:KOD

$7.90 -0.30 (-3.66%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$7.91 +0.01 (+0.13%)

As of 08/8/2025 04:10 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Quince Therapeutics NASDAQ:QNCX

$1.65 -0.02 (-1.20%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$1.68 +0.03 (+1.82%)

As of 08/8/2025 07:59 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time